182 related articles for article (PubMed ID: 21757611)
21. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
22. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
23. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra.
Cao J; Chen X; Liang J; Yu XQ; Xu AL; Chan E; Wei D; Huang M; Wen JY; Yu XY; Li XT; Sheu FS; Zhou SF
Drug Metab Dispos; 2007 Apr; 35(4):539-53. PubMed ID: 17220245
[TBL] [Abstract][Full Text] [Related]
24. Intestinal absorption mechanism of rotundic acid: Involvement of P-gp and OATP2B1.
Shang H; Sun Y; Wang Z; Zhou Y; Yang H; Ci X; Cui T; Xia Y; Gu Y; Liao M; Li Q; Si D; Liu C
J Ethnopharmacol; 2022 May; 289():115006. PubMed ID: 35051604
[TBL] [Abstract][Full Text] [Related]
25. Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism.
Shang H; Wang Z; Ma H; Sun Y; Ci X; Gu Y; Liu C; Si D
Pharm Biol; 2021 Dec; 59(1):200-208. PubMed ID: 33595422
[TBL] [Abstract][Full Text] [Related]
26. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
27. Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats.
Nielsen CU; Abdulhussein AA; Colak D; Holm R
Int J Pharm; 2016 Nov; 513(1-2):78-87. PubMed ID: 27601334
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
[TBL] [Abstract][Full Text] [Related]
29. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Collett A; Tanianis-Hughes J; Hallifax D; Warhurst G
Pharm Res; 2004 May; 21(5):819-26. PubMed ID: 15180340
[TBL] [Abstract][Full Text] [Related]
30. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
31. Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells.
Li YX; Ye LH; Jiang XH; Peng C
Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):41-7. PubMed ID: 21336515
[TBL] [Abstract][Full Text] [Related]
32. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
34. Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley rats.
Al-Ali AAA; Quach JRC; Bundgaard C; Steffansen B; Holm R; Nielsen CU
Int J Pharm; 2018 May; 543(1-2):352-360. PubMed ID: 29635055
[TBL] [Abstract][Full Text] [Related]
35. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
36. Permeability of Ciprofloxacin-Loaded Polymeric Micelles Including Ginsenoside as P-glycoprotein Inhibitor through a Caco-2 Cells Monolayer as an Intestinal Absorption Model.
Sharif Makhmal Zadeh B; Esfahani G; Salimi A
Molecules; 2018 Jul; 23(8):. PubMed ID: 30065147
[TBL] [Abstract][Full Text] [Related]
37. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
38. Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A.
Lee YJ; Chung SJ; Shim CK
Biol Pharm Bull; 2005 Apr; 28(4):760-3. PubMed ID: 15802827
[TBL] [Abstract][Full Text] [Related]
39. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Sane R; Mittapalli RK; Elmquist WF
J Pharm Sci; 2013 Apr; 102(4):1343-54. PubMed ID: 23334925
[TBL] [Abstract][Full Text] [Related]
40. Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.
Lacher SE; Gremaud JN; Skagen K; Steed E; Dalton R; Sugden KD; Cardozo-Pelaez F; Sherwin CM; Woodahl EL
J Pharmacol Exp Ther; 2014 Feb; 348(2):336-45. PubMed ID: 24297779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
